Researchers have identified a receptor protein known as CHRM1 as a key player in prostate cancer cells’ resistance to docetaxel, a commonly used chemotherapy drug to treat advanced cancer that has spread beyond the prostate. The discovery opens the door to new treatment strategies that could overcome this resistance. This could ultimately help extend the lives of those with prostate cancer, one of the leading causes of cancer deaths among men.
A team of scientists showed that blocking CHRM1 in resistant prostate cancer cell lines and an animal model based on patient-derived resistant tissue restored docetaxel’s ability to kill cells and stop tumor growth. The researchers did this by using dicyclomine, a drug that selectively inhibits CHRM1 activity. Dicyclomine is already on the market as a generic drug and is currently used to treat symptoms of irritable bowel syndrome.
“The effect was pretty dramatic in all the experimental models we tested,” said a co-senior author on the study. “And because dicyclomine already has a clinical use, this work has immediate translational potential.”
Published in the journal Cell Reports Medicine, the researchers’ findings support clinical testing to confirm whether combined use of docetaxel and dicyclomine could help overcome treatment resistance in prostate cancer patients. Docetaxel resistance can develop in prostate cancer after about six months of treatment. Chemotherapy drugs like docetaxel are among very few options available to patients with castration-resistant prostate cancer, a lethal form of the disease that no longer responds to hormone therapy.
The author said this type of combination therapy could also potentially be used for other cancers that are currently being treated with docetaxel, such as breast and lung cancer. It may also be possible to use the same combination strategy with other similar chemotherapy drugs.
In addition to testing resistant cancer cell lines, the research team also tested cells that still responded to docetaxel treatment. They found that using dicyclomine to block CHRM1 in these cells made docetaxel more efficient at killing them. The author said that this shows that prostate cancer patients could potentially benefit from a combination treatment strategy even before docetaxel resistance develops.
“What this suggests is that the lowest effective dose of docetaxel may be lower when the drug is combined with dicyclomine, compared to when docetaxel is used alone,” the author said. “Being able to use a lower dose could help reduce unwanted side effects and make treatment more manageable for patients.”
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00617-1
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fcholinergic-signaling&filter=22
Cholinergic signaling in drug resistant prostate cancer
- 991 views
- Added
Latest News
3D maps of diseased tissues…
By newseditor
Posted 06 Jul
How GLP-1 receptor agonists…
By newseditor
Posted 06 Jul
Pan-cancer proteogenomics e…
By newseditor
Posted 05 Jul
Fertility treatments could…
By newseditor
Posted 05 Jul
Extended-release ketamine t…
By newseditor
Posted 05 Jul
Other Top Stories
A genetically encoded magnetic biosensor for dynamic gene reporting
Read more
An easy test for sickle cell disease
Read more
New method to amplify DNA to identify lesions
Read more
Sensing low toxic gas concentrations
Read more
A Metabolic Signature of Mitochondrial Dysfunction
Read more
Protocols
Pan-cancer proteogenomics c…
By newseditor
Posted 05 Jul
A systems biology-based ide…
By newseditor
Posted 05 Jul
Tongue orthotopic xenograft…
By newseditor
Posted 04 Jul
Monitoring norepinephrine r…
By newseditor
Posted 01 Jul
BicemuS: A new tool for neu…
By newseditor
Posted 26 Jun
Publications
dsRNA formation leads to pr…
By newseditor
Posted 07 Jul
BACH1 inhibits senescence,…
By newseditor
Posted 07 Jul
Bone transport induces the…
By newseditor
Posted 06 Jul
Hypothalamic neuronal activ…
By newseditor
Posted 06 Jul
Prevention of Falls in Olde…
By newseditor
Posted 05 Jul
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar